Harrison Global Holdings Signs Strategic International Business Partnership Agreement with Biotree Co., Ltd., the World's First Natural Product Drug Development Company for Metabolic Syndrome
Rhea-AI Summary
Harrison Global Holdings (NASDAQ:BLMZ), a Japanese entertainment and voice actor management company, has formed a strategic partnership with Biotree Co., Ltd., a Korean biotech firm developing natural product-based treatments for metabolic syndrome.
Biotree's lead drug candidate PH-100 has completed Phase 1 trials in the US and Phase 2A trials across 12 Korean hospitals, showing significant reduction in inflammatory markers without adverse effects. The company expects conditional approval and launch in H1 2026, pending Phase 2B results.
The partnership scope includes establishing joint ventures, developing new natural product drugs, sharing distribution channels, and supporting regulatory compliance across US, Japan, China, and Asian markets. Biotree brings strong credentials with over 50 patents, 130+ SCI papers, and multiple regulatory certifications including FDA NDI and IND.
Positive
- Strategic expansion into healthcare/biotech sector through partnership with established Korean firm
- Access to Biotree's PH-100 drug with positive Phase 1 and 2A clinical trial results
- Partnership covers multiple high-value markets including US, Japan, and China
- Biotree brings strong IP portfolio with 50+ patents and regulatory certifications
Negative
- Significant deviation from Harrison Global's core entertainment business model
- PH-100 still requires Phase 2B completion and regulatory approval
- No financial terms or partnership structure details disclosed
- Execution risks in entering new industry with different regulatory requirements
Insights
Harrison Global's partnership with Biotree represents an unusual diversification from entertainment into biotech with uncertain strategic fit.
This partnership between Harrison Global Holdings, primarily an entertainment company, and Biotree, a natural product drug developer, represents a significant strategic pivot that raises important questions about business alignment. Biotree has made notable progress with its metabolic syndrome treatment PH-100, having completed Phase 1 trials in the US and Phase 2A trials across Korean hospitals with positive inflammatory marker reduction results. The company anticipates conditional approval by first half of 2026.
What's particularly interesting is Biotree's work with Seapolynol, a marine polyphenol extracted from Gamtae seaweed, which has formed the foundation for their diverse product portfolio spanning pharmaceuticals to cosmetics. Their regulatory achievements include FDA NDI and IND certifications, plus European EFSA NFI certification, alongside an impressive intellectual property portfolio of over 50 patents and 130+ SCI-level publications.
The partnership scope includes potential joint ventures, licensing agreements, shared distribution channels, and regulatory collaboration. However, this represents a substantial departure from Harrison Global's core competencies in audio production, V-Tuber entertainment, and voice actor management. The strategic rationale for this cross-industry partnership remains unclear, as does Harrison Global's expertise in pharmaceutical development and commercialization. While diversification can be valuable, such dramatic shifts into highly regulated industries like pharmaceuticals typically require specialized knowledge and substantial capital investment, making this an unconventional and potentially risky strategic move for shareholders.
TOKYO, JAPAN / ACCESS Newswire / August 12, 2025 / Harrison Global Holdings Inc. (NASDAQ:BLMZ) ("Harrison Global" or the "Company"), a Japanese audio production, V-Tuber, entertainment, and voice actor management company, announced today that it has signed a strategic international business partnership agreement with Biotree Co., Ltd. ("Biotree"), a Korean firm developing the world's first natural product-based treatment for metabolic syndrome - including diabetes, obesity, hyperlipidemia, and hypertension.
Biotree has successfully completed Phase 1 clinical trials in the United States for PH-100, its natural product-based treatment targeting metabolic syndrome and diabetic complications. Additionally, Biotree has concluded Phase 2A clinical trials across 12 university hospitals in Korea. The Phase 2A clinical trial results confirmed a significant reduction in inflammatory markers (HS-CRP) and showed positive effects on cardiovascular disease without adverse side effects. Pending the successful completion of the ongoing Phase 2B clinical trials, the drug is expected to be conditionally approved and launch as a prescription-only treatment in the first half of 2026.
Among seaweeds, Gamtae stands out for its notable health benefits, including dementia prevention, vascular health support, and anticancer effects - often called the ocean's natural nutrient. Biotree is the first Korean company to extract "Seapolynol," a marine polyphenol, from Gamtae, and has since developed and sold a diverse range of products spanning health functional foods, pharmaceuticals, daily necessities, and cosmetics. Biotree has quietly expanded its presence in both domestic and international markets.
Since 2008, Biotree has led the industry in Korea by being the first to obtain certifications such as U.S. FDA's NDI (New Dietary Ingredient) and IND (Investigational New Drug), and the European EFSA NFI (Novel Food Ingredient) certification. It has also registered and issued over 50 patents and published over 130 SCI (Science Citation Index)-level papers.
Dr. Eui-Shin Kim, a world-renowned oncologist and a leader in nuclear medicine, serves as a senior advisor to Biotree. He served as a tenured professor at the University of Texas MD Anderson Cancer Center for 32 years and has gained recognition for his research on cancer diagnostic techniques utilizing genetic analysis and MRI. His exceptional achievements have earned him eleven honors as one of America's Best Doctors.
Harrison Global Holdings plans to actively pursue the global expansion of Biotree's new drug technology and raw materials for metabolic syndrome treatments, including exports to markets such as the US, Japan, China, and Asia. Under the partnership, the scope of operations includes, but is not limited to:
Establishing a joint venture or licensing agreement for operations in local countries
Joint development of new natural product drugs and their localization in each country
Sharing of branding, distribution channels, and technological infrastructure
Cooperation in introducing and developing local partners
Regulatory compliance, media strategy, and local PR support
Ryoshin Nakade, Co-CEO of Harrison Global Holdings, stated, "Through this partnership, we are delighted to contribute to human health by working with Biotree to complete the development of a natural metabolic syndrome treatment that has taken considerable time and investment to develop and enter the global market. We look forward to working closely with the Biotree team to support the joint development and distribution of its products."
About Harrison Global Holdings Inc.
Harrison Global Holdings Inc. (formerly BloomZ Inc.) is a holding company headquartered in the Cayman Islands, operating BloomZ Japan in Japan. BloomZ Japan is engaged in sound production for anime and games, as well as the management, training, and promotion of voice actors and VTubers. In recent years, it has also focused on developing and promoting next-generation entertainment businesses.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "will," "expects," "anticipates," "aims," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.
Harrison Global Holdings Inc. Investor Contact
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
Email: bloomz@gateway-grp.com
SOURCE: Harrison Global Holdings Inc.
View the original press release on ACCESS Newswire
FAQ
What is the strategic partnership between Harrison Global Holdings (NASDAQ:BLMZ) and Biotree?
What are the clinical trial results for Biotree's PH-100 drug?
When is Biotree's PH-100 expected to launch?
What certifications and achievements does Biotree have?
How does this partnership affect Harrison Global Holdings' business model?
